FY27 Revenue Growth: 15%
Conservative guidance of 15% revenue growth for FY27 accounts for ongoing geopolitical uncertainties affecting logistics and supply chain stability. Upside potential exists if external environment stabilizes.
SMSPHARMA / guidance tracker
Keep management guidance in view.
SMS Pharmaceuticals · forward-looking guidance across the available source record.
Research layer active
Guidance tracker
What management said would happen.
revenue
FY27 EBITDA Margin: Targeting 22%+
Management targets 22% EBITDA margin in FY27, up from 20% in FY26, driven by backward integration benefits and improved operating leverage. This would exceed the historical all-time high of 22%.
Medium-term Revenue Growth: 20-25%
Beyond FY27, management's actual target is 20-25% growth rate, with conservatism in near-term guidance due to geopolitical risks. New API launches and capacity expansion expected to drive acceleration from FY28.
New API Revenue Contribution: FY28 Onwards
Brownfield expansion with 4-5 new high-value, high-margin APIs expected to begin meaningful contribution in FY28 with further scale-up in FY29. Peptide platform and CDMO initiatives also targeting FY29 contributions.